German pharma adds drugs for rare tumors, expands U.S. footprint via $3.9B acquisition

The target is one of industry’s most notable case studies in continued product differentiation and market growth 

J&J to bring Rybrevant into two Phase III colorectal cancer studies based on Phase II data

The month also brought conversions to full approval for Retevmo and Sirturo

Plus: Readouts from Geneos, BMS and Nurix

With its first regulatory submission filed in China, the biotech is setting its next sights on global first-in-class therapies

Red Tree branches beyond West Coast sweet spot to co-lead with RA Capital in backing Biocon spinout

As pharma implements growth plan to look beyond Xtandi, rising CEO Okamura figures to execute on launches, develop in newer modalities

Mirati’s KRAS inhibitor maintains efficacy in challenging colorectal cancer indication

High risk-high reward replaced with well-defined activity in focused indications